Class Action Suit Filed Against Cardlytics (CDLX) Over Misleading Investor Communications

Class Action Lawsuit Targets Cardlytics Over Misleading Statements

Rosen Law Firm has initiated a class action lawsuit against Cardlytics, Inc. (NASDAQ: CDLX), representing investors who purchased company securities between March 14, 2024, and August 7, 2024. The lawsuit alleges that Cardlytics misled investors regarding its business operations during this period, specifically concerning its consumer engagement and revenue growth. According to the complaint, Cardlytics failed to disclose critical information about rising consumer engagement, which resulted in increased consumer incentives without a corresponding increase in billings. This disconnect raised significant concerns about the potential for slower revenue growth, which the company allegedly did not communicate to its investors.

Further complicating Cardlytics' situation, the introduction of changes to the company's Ads Decision Engine (ADE) reportedly led to underdelivery of customer budgets and inaccurate billing estimates. The lawsuit asserts that these developments contributed to a misleading narrative about the company's financial health and operational effectiveness. As the truth about the company's struggles became public, investors faced significant losses, prompting the legal action. Shareholders interested in participating as lead plaintiffs must file their motions by March 25, 2025, while those opting out can remain as absent class members. The Rosen Law Firm operates on a contingency fee basis, ensuring shareholders incur no fees unless they secure a recovery.

The implications of this lawsuit extend beyond financial recovery; they raise substantial questions about corporate governance and accountability within Cardlytics. The firm has established a reputation for advocating shareholder rights, having successfully recovered over $1 billion for investors since its inception. As the legal proceedings unfold, the focus will likely remain on how effectively Cardlytics communicates critical operational information and the impact of its business strategies on investor confidence.

In addition to the Rosen Law Firm's efforts, the Schall Law Firm has also announced a class action lawsuit against Cardlytics, citing alleged violations of the Securities Exchange Act of 1934. This lawsuit similarly addresses concerns over misleading statements made during the same timeframe, emphasizing the need for transparency in corporate communications. Affected shareholders are encouraged to reach out to the Schall Law Firm for potential claims and recovery options, as the class has yet to be certified. Investors are urged to remain vigilant as these legal developments unfold in a challenging market environment for Cardlytics.